Moneycontrol PRO

you are here: HomeNewsBusinessEarningsSee 20% EBITDA growth in FY14: Alembic Pharma

SHOW NAMES

Trending Topics

business

See 20% EBITDA growth in FY14: Alembic Pharma

In an interview to CNBC-TV18, Amin adds that the company, despite the drug pricing policy, will grow at 15 percent.

first published: Aug 7, 2013 03:50 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Nifty Snaps 6-Day Winning Streak As Markets Get In Consolidation Mode| Closing Bell Live
Kenneth Andrade picks three unusual, ignored sectors to bet on in Samvat 2082
Nifty Likely To Consolidate Until It Clears 26,000 Mark Decisively | Opening Bell Live
Nifty Slips Over 150 Points From Day's High But Gains For 6th Day| IT Stocks Surge|Closing Bell Live

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347